Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (16353)	3/3/1998 4:34:00 PM
From: WTDEC	Respond to of 32384

Henry, If Ligand could combine the two P2s and file the NDA, it would be a big positive 'surprise' for the market. ( Of course, now the possibility is in print, so maybe the market will begin to anticipate it happening.) Has anyone you are aware of (big pharma, perhaps) done that before? I must also say that I would be shocked if the upcoming news flow fails to attract more coverage from at least several more large WS firms. Regards, wtd

To: Henry Niman who wrote (16353)	3/3/1998 4:42:00 PM
From: AJAG	Respond to of 32384

Hi Henry! I guess the Amylin debacle today underscores the fact that single drug biotech companies are the riskiest investments. Gotta love the Ligands, Genzymes, ISIP ,etc that have multiple products and technologies. By the way, did you see how well the major biotech stocks did today in the face of the AMLN meltdown? AMGN, BGEN, et al all up strongly. Do you think this was short covering, now that the bad news is out on a high profile co. (AMLN), on the theory that the next biotech headline could be the positive news that reignites the group? Or did the shorts panic when the entire group did not tank on the bad news from AMLN?